"Discovering transformative medicines is not an easy task. Being at Genentech gives me courage to believe that my wildest dreams can be realized"
I joined Genentech in 2007 with an audacious hope to develop innovative medicines by combining my knowledge in molecular biology and animal physiology with Genentech’s cutting-edge protein engineering technologies. After 9+ years of drug discovery effort for metabolic and fibrotic diseases with some exciting progress, my group is currently studying immune-modulatory mechanisms in adaptive tissue remodeling and cancer pathogenesis.
Working at Genentech for me so far is really like living a dream as a molecular biologist; all the resources are there, and the only limit is my imagination. Genentech is an exciting and unique place where creative and ambitious minds work together to convert wild imaginations into reality.
Being a postdoc mentor expands our ability to dig deep into the mechanistic basis of complex biological systems. Addressing fundamental questions in biology using cutting-edge technologies is itself an exciting pursuit. At the same time, knowledge that spawns from pure basic science projects could give unexpected insights into drug discovery efforts.
J Biol Chem. 2016 Mar 11;291(11):5986-96
Science Translational Medicine; 3(113)113ra126.
Our current working hypothesis is that pharmacologic manipulation of stromal cell activity and extracellular matrix in tumor microenvironment may allow patient’s own immune cells to eradicate tumors effectively and restore normal tissue homeostasis, especially in the context of cancer immunotherapy. We are dissecting biological mechanisms governing the evolution of tumor microenvironment and the cancer pathogenesis. At the same time, we are actively applying our knowledge and expertise in drug development to discover mechanism-based therapeutic molecules.